Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2007
10/03/2007CN100340299C Method for preparing radioactive nuclide magnetic microsphere used in vivo
10/03/2007CN100340297C Anticarcinogenic internal implant agent
10/03/2007CN100340296C Anticarcinogenic internal implant agent
10/03/2007CN100340291C F1t4(VEGFR-3) as target for tumor imaging and anti-tumor therapy
10/03/2007CN100340274C Application of dye yam extract in preparation of anti-tumor medicine
10/03/2007CN100340246C Globefish oil preparation and its preparing method
10/03/2007CN100340239C Andrographolide dispersing tablets
10/02/2007US7276602 Isothiazole derivatives useful as anticancer agents
10/02/2007US7276594 Nucleic acid-containing complex
10/02/2007US7276593 Proteins and nucleic acids encoding same
10/02/2007US7276537 Formulations of anthraquinone derivatives
10/02/2007US7276533 Compositions useful for the treatment of pathologies responding to the activation of PPAR-gamma receptor
10/02/2007US7276524 Compounds as antumor agents or immunosuppressants
10/02/2007US7276513 Steroidal compounds for inhibiting steroid sulphatase
10/02/2007US7276512 anti-tumour properties; surprising in vitro and in vivo cytotoxic activity
10/02/2007US7276509 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic
10/02/2007US7276507 Pyridopyrazines and the use thereof as kinase inhibitors
10/02/2007US7276504 Nasally administering an imidazotriazinone substituted with an (alkoxy)(aminosulfonyl)phenyl group for treating diseases including psoriasis, female infertility, diabetes, glaucoma, cystic fibrosis, pre-eclampsia, Parkinsonism, tinnitus, pain, gastric motility disorders, and pulmonary hypertension
10/02/2007US7276502 For therapy and prophylaxis of immunodeficiency disorders, inflammatory diseases, allergic diseases, autoimmune diseases, proliferative disorders, immunologically-mediated diseases, or respiratory disorders
10/02/2007US7276500 Substituted amides, their preparation and use
10/02/2007US7276499 Sulfur-containing taxanes, specially covalently bonded to a cell binding agent for targeted delivey to specific cell populations
10/02/2007US7276494 Photodynamic therapy; anticancer agents, vision defects, autoimmune disease, restenosis, skin disorders; cancer vaccine; medical diagnosis
10/02/2007US7276490 Administering to the cancer cell a pharmaceutical formulation of a nucleic acid encoding and expressing a prostacyclin synthase as an active ingredient and a nucleic acid encoding and expressing a cyclooxygenase-2
10/02/2007US7276475 Remodeling and glycoconjugation of peptides
10/02/2007US7276364 Nucleic acids encoding endotheliases, endotheliases and uses thereof
10/02/2007US7276252 Material handling of toxic drugs; multilayer forms
10/02/2007US7276248 Conjugate having a cleavable linkage for use in a liposome
10/02/2007US7276241 Anticancer agents; administering polypeptide antagonist
10/02/2007CA2413424C Substituted bicyclic derivatives for the treatment of abnormal cell growth
10/02/2007CA2401229C Aryl fused azapolycyclic compounds
10/02/2007CA2387357C Derivatives of pyrazolo[4,3-d]pyrimidin-7-ones which inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterase
10/02/2007CA2330756C Indole derivatives and their use for the treatment of malignant and other diseases based on pathological cell proliferation
10/02/2007CA2290537C Use of taurolidine for treatment of leukemias
10/02/2007CA2262421C Substituted pyrrolopyrimidines and processes for their preparation
10/02/2007CA1341552C Method of producing human-human hybridomas, the production of monoclonal and polyclonal antibodies therefrom, and therapeutic use thereof
09/2007
09/27/2007WO2007109783A2 Substituted pyrimidine kinase inhibitors
09/27/2007WO2007109609A2 Method for inhibiting angiogenesis
09/27/2007WO2007109567A1 Anti-tat226 antibodies and immunoconjugates
09/27/2007WO2007109434A1 Besylate salt form of 1- (5-tert-butyl-2-p-t0lyl-2h-pyraz0l-3-yl) -3- (4- (6- (morpholin-4-yl-methyl) -pyrid in- 3 -yl) -naphthalen- 1-yl) -urea and polymorphs thereof
09/27/2007WO2007109330A2 S1p receptor modulating compounds
09/27/2007WO2007109303A2 Formulations of lymphokines and method of use thereof for local or both local and systemic control of proliferative cell disorders
09/27/2007WO2007109142A2 M3 muscarinic receptor antagonists for treating tumors
09/27/2007WO2007109071A2 Hydroxylated polymethoxyflavone compositions
09/27/2007WO2007109045A1 Heterocyclic organic compounds for the treatment of in particular melanoma
09/27/2007WO2007108754A1 Crystalline forms of n- {2-tert -butyl -1- [ (4,4- dif luorocyclohexyl) methyl] -lh-benzimidazol-5- yl}ethanesulfonamide salts
09/27/2007WO2007108727A1 Method for monitoring the effect of compounds on foxc2 expression
09/27/2007WO2007108275A1 Water having anticancer action and method for producing the same
09/27/2007WO2007108272A1 Kit for cancer therapy and pharmaceutical composition for cancer therapy
09/27/2007WO2007108152A1 High functional bispecific antibody
09/27/2007WO2007107998A1 5-aminolevulinic acid salts and their use
09/27/2007WO2007107764A1 Reversibly inhibited antibodies for immune cell stimulation
09/27/2007WO2007107594A2 Six-membered heterocycle substituted trifluoroethanone derivatives as histone deacetylase (hdac) inhibitors
09/27/2007WO2007107545A1 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
09/27/2007WO2007107543A1 Inhibitors of the interaction between mdm2 and p53
09/27/2007WO2007107346A1 Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
09/27/2007WO2007107298A1 Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
09/27/2007WO2007107161A2 Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
09/27/2007WO2007089149A3 Water-soluble cc-1065 analogs and their conjugates
09/27/2007WO2007085833A3 Pyrimidine derivatives
09/27/2007WO2007079164A3 Protein kinase inhibitors
09/27/2007WO2007068728A3 N-substituted pyrrolopyridinones active as kinase inhibitors
09/27/2007WO2006043083A8 Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy
09/27/2007US20070225376 Medicinal Agent
09/27/2007US20070225311 Condensation of 7-t-butoxyiminomethylcamptothecin in position 20 with a cyclopeptide containing the RGD sequence; selective cytotoxic activity on human tumor cell lines; antitumor;
09/27/2007US20070225303 8-Oxoadenine Compound
09/27/2007US20070225300 HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
09/27/2007US20070225265 Novel Macrocycles for the Treatment of Cancer
09/27/2007US20070225222 Use of heparin-binding domain of fibronectin for diagnosis and treatment of cancer
09/27/2007US20070225221 Methods of treatment using specific binding agents of human angiopoietin-2
09/27/2007US20070225218 Extracellular Messengers
09/27/2007US20070224279 Stabilization of chemical compounds using nanoparticulate formulations
09/27/2007US20070224263 Aminoalkylphosphonates and related compounds as Edg receptor agonists
09/27/2007US20070224218 Viral antigens
09/27/2007US20070224214 Composition Exerting Physiological Activity Via Biological Immune Mechanism
09/27/2007US20070224202 contains the idiotype of the HE2 antibody directed against the cellular membrane antigen Ep-CAM
09/27/2007DE60125416T2 Stabilisierte formulierungen von 6-hydroxy-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophen und deren salze Stabilized formulations of 6-hydroxy-3- (4- (2- (piperidin-1-yl) ethoxy) phenoxy) -2- (4-methoxyphenyl) benzo (b) thiophene and their salts
09/27/2007DE102006014543A1 Funktionelle Lebensmittel gegen Tumore Functional foods against tumors
09/27/2007DE102006014165A1 Neue Isooxazol-Derivate und deren Verwendungen New isoxazole derivatives and uses thereof
09/27/2007DE102006012617A1 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate 4- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives
09/27/2007CA2648829A1 Crystalline forms of n-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1h-benzimidazol-5-yl}ethanesulfonamide salts
09/27/2007CA2647779A1 Lipid based drug delivery systems comprising phospholipase a2 degradable lipids that perform an intramolecular cyclization reaction upon hydrolysis
09/27/2007CA2646589A1 Inhibition of tumour growth
09/27/2007CA2646469A1 S1p receptor modulating compounds
09/27/2007CA2645892A1 Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
09/27/2007CA2645831A1 Anti-tat226 antibodies and immunoconjugates
09/27/2007CA2645728A1 Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
09/27/2007CA2645546A1 Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases
09/27/2007CA2645265A1 Water having anticancer action and method for producing the same
09/27/2007CA2644649A1 Cyclic-alkylaminederivatives as inhibitors of the interaction between mdm2 and p53
09/27/2007CA2644643A1 Inhibitors of the interaction between mdm2 and p53
09/27/2007CA2644356A1 Heterocyclic organic compounds for the treatment of in particular melanoma
09/26/2007EP1837025A2 Method of treating cancer using kinase inhibitors
09/26/2007EP1836225A1 Kir-binding agents and methods of use thereof
09/26/2007EP1836201A1 Pyrrolidine inhibitors of iap
09/26/2007EP1836199A1 Thiazole and isothiazole derivatives that modulate the activity of cdk, gsk and aurora kinases
09/26/2007EP1836194A1 4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy
09/26/2007EP1836191A1 Pyrazolylamino substituted quinazoles for the treatment of cancer
09/26/2007EP1836188A1 Pyrazole derivatives as that modulate the activity of cdk, gsk and aurora kinases
09/26/2007EP1836183A2 Spiro derivatives as lipoxygenase inhibitors
09/26/2007EP1836170A1 N-((2z)-2-((4-hydroxyphenyl)imino)-1,2-dihydro-3-pyridinyl)-4-methoxybenzenesulfonamide crystalline form 2
1 ... 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 ... 2211